Terms: = Ovarian cancer AND NTRK1, ENSG00000198400, 4914, P04629, TRK1, MTC, DKFZp781I14186, p140-TrkA, TRKA, TRK AND Treatment
8 results:
1. Hydrazide-hydrazones as Small Molecule Tropomyosin Receptor Kina se A (trka) Inhibitors: Synthesis, Anticancer Activities,
Alam MS; Lee DU
Med Chem; 2022; 19(1):47-63. PubMed ID: 35490310
[TBL] [Abstract] [Full Text] [Related]
2. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
[TBL] [Abstract] [Full Text] [Related]
3. A novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple solid tumors: cabozantinib.
Roy S; Narang BK; Rastogi SK; Rawal RK
Anticancer Agents Med Chem; 2015; 15(1):37-47. PubMed ID: 25181996
[TBL] [Abstract] [Full Text] [Related]
4. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
Grüllich C
Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
[TBL] [Abstract] [Full Text] [Related]
5. Trabectedin for the treatment of relapsed ovarian cancer.
Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P
Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
[TBL] [Abstract] [Full Text] [Related]
6. Incorporating direct and indirect evidence using bayesian methods: an applied case study in ovarian cancer.
Griffin S; Bojke L; Main C; Palmer S
Value Health; 2006; 9(2):123-31. PubMed ID: 16626416
[TBL] [Abstract] [Full Text] [Related]
7. A metastatic neuroblastoma model in SCID mice.
Bogenmann E
Int J Cancer; 1996 Jul; 67(3):379-85. PubMed ID: 8707412
[TBL] [Abstract] [Full Text] [Related]
8. Isozyme-specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines.
Morgan AS; Ciaccio PJ; Tew KD; Kauvar LM
Cancer Chemother Pharmacol; 1996; 37(4):363-70. PubMed ID: 8548883
[TBL] [Abstract] [Full Text] [Related]
